Fig. 5 | Oncogene

Fig. 5

From: Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option

Fig. 5

Combined blocking of PVR and PVRL2 on primary AML blasts increases the cytotoxic effects of HD-PBMCs. Mononuclear cells containing at least 75% blasts from bone marrow aspirates of ten different, newly diagnosed AML patients were stained with CMFDA (CellTracker™), mixed with HD-PBMCs as effector cells, and incubated for 72 h. Blocking of PVR and PVRL2 alone could increase the specific lysis of primary blasts in four (a, b, c, f) of the ten analyzed patients, and augment the anti-leukemic effect of the BiTE® antibody construct AMG 330 in five of nine patients (a–e). The sample of patient (f) was CD33 negative, and therefore excluded from the AMG 330 experiment. Results are depicted as the mean of technical triplicates ± SD of dead target cells

Back to article page